Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trial
Shalini Makawita(The University of Texas MD Anderson Cancer Center), Milind Javle(The University of Texas MD Anderson Cancer Center), Terry Cho(QED Technologies (United States)), Lipika Goyal(Stanford Medicine), Do‐Youn Oh(Seoul National University Hospital), Michael F. Howland(Massachusetts Institute of Technology), Ghassan K. Abou‐Alfa(Memorial Sloan Kettering Cancer Center), Teresa Macarulla(Vall d'Hebron Hospital Universitari), Sameek Roychowdhury(The Ohio State University Wexner Medical Center), Amit Pande(QED Technologies (United States)), Ai Li(QED Technologies (United States)), Saeed Sadeghi(University of California, Los Angeles), Ivan Borbath, Allen Lee Cohn(Rocky Mountain Cancer Centers), Rachna T. Shroff(University of Arizona)
Cited by 91
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Landscape of Microsatellite Instability Across 39 Cancer Types
|JCO Precision Oncology|2017|1.5k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k